Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBITDA (2016 - 2025)

Historic EBITDA for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to -$27.9 million.

  • Perspective Therapeutics' EBITDA fell 4951.7% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.7 million, marking a year-over-year decrease of 10618.29%. This contributed to the annual value of -$90.9 million for FY2024, which is 12199.26% down from last year.
  • Per Perspective Therapeutics' latest filing, its EBITDA stood at -$27.9 million for Q3 2025, which was down 4951.7% from -$24.0 million recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' EBITDA registered a high of $1.3 million during Q2 2021, and its lowest value of -$45.0 million during Q4 2024.
  • Moreover, its 5-year median value for EBITDA was -$9.8 million (2023), whereas its average is -$11.7 million.
  • In the last 5 years, Perspective Therapeutics' EBITDA skyrocketed by 21320.44% in 2021 and then crashed by 60937.5% in 2023.
  • Over the past 5 years, Perspective Therapeutics' EBITDA (Quarter) stood at -$1.6 million in 2021, then tumbled by 243.79% to -$5.6 million in 2022, then crashed by 107.72% to -$11.7 million in 2023, then crashed by 285.27% to -$45.0 million in 2024, then skyrocketed by 38.06% to -$27.9 million in 2025.
  • Its EBITDA stands at -$27.9 million for Q3 2025, versus -$24.0 million for Q2 2025 and -$21.8 million for Q1 2025.